Mergers & acquisitions
Once the deal is done, the company will be renamed MoonLake Immunotherapeutics and trade on the Nasdaq under the ticker symbol MLTX.
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
Investment firm Avoro Capital has raised concerns that the $180 per-share price Merck is paying Acceleron Pharma undervalues the rare-disease focused company.
Merck will acquire Acceleron for the expected $180 per share in cash for an approximate total equity value of $11.5 billion.
Reports emerged late Wednesday afternoon that Merck emerged as the winning suitor with a deal valued at about $11 billion.
AstraZeneca’s Alexion plans to buy all remaining equity in Caelum Biosciences and pick up Caelum’s CAEL-101 in the process.
The news sparked a mini-surge in shares of I-Mab, which were up 7.8% in pre-market U.S trading on September 28.
Amicus Therapeutics is launching a next-generation genetic medicine company called Caritas Therapeutics, Inc. through a merger deal with ARYA Sciences Acquisition Corp IV.
This Was the World’s First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction.
Novartis expands its optogenetics portfolio with the acquisition of Arctos Medical, cementing its commitment to optogenetics-based therapies to restore vision to patients with advanced blindness.
PRESS RELEASES